AZN

AstraZeneca (AZN)

AstraZeneca PLC

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:AZN

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/22	20 : 00	Business Wire	AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024	NASDAQ:AZN	AstraZeneca PLC
2024/05/22	07 : 44	Business Wire	アストラゼネカ、2030年までに総収益800億ドルを達成し、2030年以降も持続的な成長を実現するという野心的な目標を設定	NASDAQ:AZN	AstraZeneca PLC
2024/05/22	00 : 37	Business Wire	AstraZeneca strebt für 2030 einen Gesamtumsatz von 80 Milliarden US-Dollar und ein nachhaltiges Wachstum nach 2030 an	NASDAQ:AZN	AstraZeneca PLC
2024/05/22	00 : 36	Business Wire	AstraZeneca prévoit de réaliser un chiffre d’affaires total de 80 milliards de dollars d’ici 2030 et d’atteindre une croissance continue après 2030	NASDAQ:AZN	AstraZeneca PLC
2024/05/21	20 : 18	IH Market News	CalPERS to Oppose Exxon Mobil Directors; Microsoft Unveils Copilot+ PCs with AI Focus, and More News	NASDAQ:AZN	AstraZeneca PLC
2024/05/21	19 : 08	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AZN	AstraZeneca PLC
2024/05/21	15 : 00	Business Wire	AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030	NASDAQ:AZN	AstraZeneca PLC
2024/05/20	19 : 32	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AZN	AstraZeneca PLC
2024/05/20	06 : 17	Business Wire	New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease	NASDAQ:AZN	AstraZeneca PLC
2024/05/13	20 : 16	IH Market News	Arm Sets 2025 Target for AI Chip Development, Amazon and Microsoft Commit Billions to French Investments, and More	NASDAQ:AZN	AstraZeneca PLC
2024/05/06	15 : 00	GlobeNewswire Inc.	Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca	NASDAQ:AZN	AstraZeneca PLC
2024/05/02	20 : 00	Business Wire	CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial	NASDAQ:AZN	AstraZeneca PLC
2024/05/01	20 : 05	Business Wire	AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio	NASDAQ:AZN	AstraZeneca PLC
2024/04/29	20 : 00	Business Wire	ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow	NASDAQ:AZN	AstraZeneca PLC
2024/04/25	21 : 00	PR Newswire (US)	AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	NASDAQ:AZN	AstraZeneca PLC
2024/04/25	20 : 53	IH Market News	U.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy Forecast	NASDAQ:AZN	AstraZeneca PLC
2024/04/25	20 : 52	IH Market News	Southwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on Earnings	NASDAQ:AZN	AstraZeneca PLC
2024/04/25	15 : 00	Business Wire	Q1 2024 results	NASDAQ:AZN	AstraZeneca PLC
2024/04/16	20 : 00	Business Wire	IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial	NASDAQ:AZN	AstraZeneca PLC
2024/04/12	20 : 05	IH Market News	Paramount Global Board Shrinks, Morgan Stanley Faces Regulatory Probe, and More News	NASDAQ:AZN	AstraZeneca PLC
2024/04/11	20 : 24	IH Market News	Costco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More News	NASDAQ:AZN	AstraZeneca PLC
2024/04/11	20 : 00	Business Wire	FASENRA approved for treatment of children aged 6 to 11 with severe asthma	NASDAQ:AZN	AstraZeneca PLC
2024/04/06	12 : 10	Business Wire	ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors	NASDAQ:AZN	AstraZeneca PLC
2024/04/06	10 : 43	Business Wire	ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors	NASDAQ:AZN	AstraZeneca PLC
2024/04/05	20 : 00	Business Wire	IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial	NASDAQ:AZN	AstraZeneca PLC
2024/04/02	20 : 00	Business Wire	Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer	NASDAQ:AZN	AstraZeneca PLC
2024/04/02	15 : 00	Business Wire	Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer	NASDAQ:AZN	AstraZeneca PLC
2024/04/01	20 : 00	Business Wire	VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH	NASDAQ:AZN	AstraZeneca PLC
2024/03/27	19 : 54	IH Market News	GameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More News	NASDAQ:AZN	AstraZeneca PLC
2024/03/26	20 : 20	IH Market News	Super Micro Computer and Seagate Shares Surge on Analyst Optimism in Pre-Market Trading, and Latest News	NASDAQ:AZN	AstraZeneca PLC